학술논문
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
BRIEF REPORT
BRIEF REPORT
Document Type
Report
Author
Arashiro, Takeshi; Arima, Yuzo; Kuramochi, Jin; Muraoka, Hirokazu; Sato, Akihiro; Chubachi, Kumi; Yanai, Atsushi; Arioka, Hiroko; Uehara, Yuki; Ihara, Genei; Kato, Yasuyuki; Yanagisawa, Naoki; Ueda, Akihiro; Kato, Hideaki; Oka, Hideaki; Nishida, Yusuke; Nidaira, Yuki; Asami, Takahiro; Jinta, Torahiko; Nakamura, Akira; Oba, Kunihiro; Taniyama, Daisuke; Yamamoto, Kei; Tanaka, Katsushi; Ueshima, Kankuro; Fuwa, Tetsuji; Stucky, Ashley; Suzuki, Tadaki; Smith, Chris; Hibberd, Martin; Ariyoshi, Koya; Suzuki, Motoi
Source
Open Forum Infectious Diseases. June 2023, Vol. 10 Issue 6
Subject
Language
English
ISSN
2328-8957
Abstract
Although mRNA vaccines against coronavirus disease 2019 (COVID-19) initially showed high efficacy and effectiveness, waning immunity and the repeated emergence of variants with immune escape capacity caused concern [1]. To [...]
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). Keywords. COVID-19; SARS-CoV-2; SARS-CoV-2 variants; test-negative design; vaccine effectiveness.
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). Keywords. COVID-19; SARS-CoV-2; SARS-CoV-2 variants; test-negative design; vaccine effectiveness.